Biopharma

Risk for Postpartum CVD Readmissions Higher for Twin Pr...

MONDAY, Feb. 10, 2025 -- Twin pregnancies have increased risks for cardiovascul...

Pain Linked to Increased Odds of Cigarette, Cannabis Us...

MONDAY, Feb. 10, 2025 -- Among cancer survivors, pain is associated with an inc...

Opioid Rx in the ED Slightly Raises Risk for Future Opi...

MONDAY, Feb. 10, 2025 -- Emergency department opioid prescriptions are associat...

STAT+: FDA cites Indian ingredients supplier for deleti...

The FDA warning highlights ongoing anxiety over quality control among pharmaceut...

AbbVie, Pfizer gain FDA OK for novel antibiotic

The drug is cleared to treat complicated intra-abdominal infections, including t...

Axsome secures top drug’s future with Teva patent settl...

Shares in the brain drug developer rose by more than 20% Monday on news of the d...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab...

Novartis debuts €40M viral vector plant in Slovenia, pa...

Novartis opened the doors to a €40 million ($41.2 million) viral vector facility...

FDA amplifies BD atherectomy safety alert following 4 d...

According to the agency, BD has reported 30 serious injuries and four deaths lin...

NIH caps 'indirect costs' in biomedical research grants...

A new initiative rolled out under President Donald Trump’s administration is cut...

Merck KGaA sets its sights on acquisition of Ogsiveo-ma...

Merck KGaA is said to be in advanced talks to acquire cancer and are disease spe...

Axsome shares jump as settlement will keep Teva's Auvel...

Shares of Axsome Therapeutics jumped by more than 20% after the company resolved...

Applications for new human medicines under evaluation: ...

Applications for new human medicines under evaluation: February 2025

Medicines for human use under evaluation

Medicines for human use under evaluation

Globus Medical to buy neurostim developer Nevro for $250M

With Globus paying $5.85 for each of Nevro’s outstanding shares, that amounts to...

Boehringer widens fibrosis drug’s approval path after b...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibr...

Pharmacovigilance Risk Assessment Committee (PRAC): 10 ...

Pharmacovigilance Risk Assessment Committee (PRAC): 10 - 13 February 2025, Europ...

Agenda of the PRAC meeting 10-13 February 2025

Agenda of the PRAC meeting 10-13 February 2025

STAT+: A check-in on health insurers’ medical costs, an...

This week in health care business news: Rising costs hit health insurers, United...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Ituxredi, rituximab, D...

Pliant shares collapse as company halts fibrosis drug s...

In what one analyst called a “unique situation,” the company stopped dosing pati...

MaaT Pharma : Pioneering microbiome-driven therapy as n...

CEO Hervé Affagard discusses MaaT Pharma's new approach to microbiome-driven th...

Is it time for HLS to embrace industry-specific cloud?

Experts from Wilco Source and CitiusTech discuss how AWS and Salesforce’s indust...

LQMs: A new era of drug discovery and drug development?

Andrea Bortolato of $5.6 billion startup SandboxAQ on the opportunity to transfo...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.